Cellistic And Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufacturing capability, including existing facility and all related personnel.
Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform
Collaboration combines Quell's pioneering autologous multi-modular Treg cell therapy platform and Cellistic™'s expertise in iPSC cell therapy platform development and scale-up
Ncardia Launches Cellistic™ — Purpose-Built To Make Large-Scale Allogeneic Cell Therapy Production A Reality Today
Ncardia launches Cellistic™, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.
Ncardia Appoints Andy Holt as Chief Commercial Officer
Ncardia, iPSC technology leader, taps industry veteran to drive growth in cell therapy and drug discovery markets.
Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings
Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide.
Kiniciti raises additional capital from Biospring Partners to fund its global platform serving the Cell & Gene Therapy Industry
Kiniciti, a Welsh, Carson, Anderson & Stowe (“WCAS”) platform company that invests in cell and gene therapy innovation, announced today that Biospring Partners has joined WCAS as an investor in Kiniciti. Dr. Michelle Dipp, Biospring’s Managing Partner, will serve on Kiniciti’s Board of Directors.
Kiniciti Welcomes Two Cell and Gene Therapy Industry Leaders to its Advisory Board
Kiniciti, a Welsh, Carson, Anderson & Stowe (“WCAS”) platform company that invests in non-therapeutic companies supporting Cell and Gene Therapy innovation, announced the formation of an advisory board and appointment of two inaugural members: Denis Bedoret, PhD, chief executive officer of Imcyse, and Andrew Knudten, chief operating officer of Jaguar Gene Therapy.
Welsh, Carson, Anderson & Stowe Commits $250 Million in a Strategic Partnership with Kiniciti, a Newly-Formed Platform Investing in Cell and Gene Therapy Companies
Welsh, Carson, Anderson & Stowe (“WCAS”), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today that it is committing up to $250 million to a strategic partnership with Kiniciti, a newly-formed platform. Kiniciti will invest in non-therapeutic companies supporting cell and gene therapy (“CGT”) innovation which have the potential to transform the cell and gene therapy ecosystem and deliver the promise of CGT to impact patients’ lives.